Savant Capital’s Amneal Pharmaceuticals AMRX Stock Holding History

Savant Capital’s Portfolio AMRX Stock Details AMRX Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2024 Q2	–	Sell	-10,938	Closed	-$66.3K	–	1266
2024 Q1	$66.3K	Buy	+10,938	New	+$61.7K	﹤0.01%	1092

Other funds holding AMRX

UBS Group Zurich, Switzerland $786B AUM 40.34% 1-Year Est. Return

Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

TGA

TPG GP A Fort Worth, Texas $5B AUM 58.56% 1-Year Est. Return

BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return

RCMNY

Rubric Capital Management (New York) New York $10.9B AUM 70.31% 1-Year Est. Return

Citadel Advisors Miami, Florida $875B AUM 40.89% 1-Year Est. Return

Fosun International Hong Kong, China $446M AUM 13.33% 1-Year Est. Return

Dimensional Fund Advisors Austin, Texas $552B AUM 44.19% 1-Year Est. Return

Neuberger Berman Group New York $150B AUM 40.08% 1-Year Est. Return

Geode Capital Management Boston, Massachusetts $1.88T AUM 44.46% 1-Year Est. Return

Savant Capital's AMRX Position: Q2 2024 in Review

Savant Capital sold out of Amneal Pharmaceuticals (AMRX) in Q2 2024, closing a stake of 10,938 shares — an estimated $66.3K sold.

Savant Capital first reported a position in AMRX in Q1 2024 and held it in 1 quarter. The position peaked at $66.3K in Q1 2024. 181 funds tracked by Wall St. Rank hold AMRX as of Q2 2024.

Savant Capital reported no remaining Amneal Pharmaceuticals position as of Q2 2024 after selling out during the quarter.
Savant Capital sold 10,938 Amneal Pharmaceuticals shares in Q2 2024, an estimated $66.3K.
Savant Capital first reported a position in Amneal Pharmaceuticals in Q1 2024 and held it in 1 quarter.
Savant Capital's Amneal Pharmaceuticals position peaked at $66.3K in Q1 2024.
181 funds tracked by Wall St. Rank held Amneal Pharmaceuticals as of Q2 2024.

Based on Savant Capital's 13F filing for Q2 2024, filed 5 Aug 2024.